Arthex Biotech
Arthex Biotech develops RNA-based medicines, specifically anti-miR oligonucleotides, to treat diseases with unmet medical needs. Its lead investigational program focuses on Myotonic Dystrophy Type 1 (DM1) by targeting upregulated microRNA to address the root cause of the disease. The company utilizes a delivery system where oligonucleotides are conjugated to fatty acids to improve uptake in muscle tissue at low doses.
Biotechnology
Pharmaceuticals
Life Sciences
Funding summary
- Total raised
- €78.2M
- Funding rounds
- 4
Investors in Arthex Biotech
Investors on record for Arthex Biotech. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Arthex Biotech?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors